Copyright
©The Author(s) 2022.
World J Gastroenterol. Jun 21, 2022; 28(23): 2582-2596
Published online Jun 21, 2022. doi: 10.3748/wjg.v28.i23.2582
Published online Jun 21, 2022. doi: 10.3748/wjg.v28.i23.2582
Table 1 Clinical characteristics of Crohn‘s disease patients with endoscopic remission
| Variable | Week 14 (after initial IFX therapy) | Week 54 (after initial IFX therapy) n = 54 | ||||
| Total, n = 93 | ER at week 54, n = 67 | EA at week 54, n = 26 | Total, n = 54 | ER at week 108, n = 42 | EA at week 108, n = 12 | |
| Median age in yr, mean ± SD | 28.96 ± 9.37 | 29.03 ± 10.09 | 28.77 ± 7.39 | 27.57 ± 10.13 | 26.93 ± 9.87 | 29.83 ± 11.13 |
| Course in yr, median (IQR) | 3.0 (1.0, 6.0) | 2.0 (1.0, 6.0) | 3.5 (2.0, 8.3) | 2.0 (1.0, 5.0) | 2.0 (1.0, 5.0) | 2.0 (1.3, 8.5) |
| Male sex, n (%) | 55 (59.1) | 43 (64.2) | 12 (46.2) | 35 (64.8) | 28 (66.7) | 7 (58.3) |
| Disease location, n (%) | ||||||
| L1 (terminal ileum) | 18 (19.4) | 14 (20.9) | 4 (15.4) | 10 (18.5) | 9 (21.4) | 1 (8.3) |
| L2 (colon) | 11 (11.8) | 6 (9.0) | 5 (19.2) | 5 (9.3) | 4 (9.5) | 1 (8.3) |
| L3 (ileocolon) | 64 (68.8) | 47 (70.1) | 17 (65.4) | 39 (72.2) | 29 (69.0) | 10 (83.3) |
| L4 (upper digestive tract) | 22 (23.7) | 15 (22.4) | 7 (26.9) | 14 (25.9) | 11(26.2) | 3 (25.0) |
| Disease behavior, n (%) | ||||||
| B1 (no) | 19 (20.4) | 15 (22.4) | 4 (15.4) | 13 (24.1) | 9 (21.4) | 4 (33.3) |
| B2 (stenosis) | 11 (11.8) | 9 (13.4) | 2 (7.7) | 6 (11.1) | 5 (11.9) | 1 (8.3) |
| B3 (penetration) | 40 (43.0) | 27 (40.3) | 13 (50.0) | 23 (42.6) | 18 (42.9) | 5 (41.7) |
| B2 (stenosis) + B3 (penetration) | 23 (24.7) | 16 (23.9) | 7 (26.9) | 12 (22.2) | 10 (23.8) | 2 (16.7) |
| Perianal diseases, n (%) | 55 (59.1) | 38 (56.7) | 17 (65.4) | 32 (59.3) | 25 (59.5) | 7 (58.3) |
| Previous medical therapy, n (%) | 64 (68.8) | 46 (68.7) | 18 (69.2) | 34 (63.0) | 25 (59.5) | 9 (75.0) |
| Previous surgical therapy, n (%) | 15 (16.1) | 11 (16.4) | 4 (15.4) | 8 (14.8) | 8 (19.0) | 0 (0.0) |
| Laboratory indicators, mean ± SD | ||||||
| Fecal calprotectin, μg/g | 399.96 ± 562.47 | 178.62 ± 242.38 | 970.35 ± 734.49 | 353.17 ± 557.71 | 178.57 ± 276.56 | 964.25 ± 830.56 |
| IFX trough level, μg/ml | 6.12 ± 3.72 | 7.23 ± 3.48 | 3.25 ± 2.67 | 3.80 ± 2.25 | 4.37 ± 2.02 | 1.80 ± 1.90 |
| White blood count, × 109/L | 5.32 ± 1.87 | 5.16 ± 1.47 | 5.73 ± 2.65 | 5.27 ± 1.41 | 5.27 ± 1.43 | 5.28 ± 1.41 |
| Hematoglobin, g/L | 128.37 ± 20.42 | 130.96 ± 20.03 | 121.69 ± 20.27 | 136.59 ± 16.06 | 136.79 ± 16.94 | 135.92 ± 13.13 |
| Platelet, × 109/L | 210.66 ± 69.77 | 202.36 ± 58.34 | 232.04 ± 90.94 | 205.02 ± 46.19 | 204.62 ± 45.82 | 206.42 ± 49.54 |
| Erythrocyte sedimentation rate, mm/h | 9.88 ± 12.25 | 6.89 ± 7.96 | 17.46 ± 17.28 | 7.31 ± 10.35 | 6.33 ± 6.89 | 10.75 ± 17.97 |
| Albumin, g/L | 42.13 ± 4.17 | 42.65 ± 3.93 | 40.77 ± 4.54 | 44.51 ± 3.40 | 44.99 ± 3.38 | 42.85 ± 3.02 |
| C-reactive protein, mg/dl | 2.98 ± 5.43 | 1.82 ± 2.77 | 5.96 ± 8.69 | 1.99 ± 3.18 | 1.23 ± 1.79 | 4.66 ± 5.19 |
- Citation: Cao WT, Huang R, Liu S, Fan YH, Xu MS, Xu Y, Ni H. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy. World J Gastroenterol 2022; 28(23): 2582-2596
- URL: https://www.wjgnet.com/1007-9327/full/v28/i23/2582.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i23.2582